Recap: Amneal Pharmaceuticals Q3 Earnings

Shares of Amneal Pharmaceuticals AMRX rose 1.0% in pre-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share rose 300.00% over the past year to $0.16, which beat the estimate of $0.12.

Revenue of $519,294,000 up by 37.28% from the same period last year, which beat the estimate of $482,110,000.

Guidance

The upcoming fiscal year's EPS expected to be between $0.55 and $0.65.

The upcoming fiscal year's revenue expected to be between $1,950,000,000 and $2,000,000,000.

How To Listen To The Conference Call

Date: Nov 06, 2020

Time: 08:30 AM

ET Webcast URL: https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&referrer=https%3A%2F%2Finvestors.amneal.com%2F&eventid=2631181&sessionid=1&key=BC4BD245F0CA91CDC810C8ABE15BF9A8&regTag=&sourcepage=register

Recent Stock Performance

Company's 52-week high was at $5.79

Company's 52-week low was at $2.40

Price action over last quarter: Up 12.93%

Company Description

Amneal Pharmaceuticals Inc is a generic pharmaceutical manufacturer. The company's reportable segments are Generic Products and Specialty products. Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals, and Specialty segment is engaged in the development, promotion, sale and distribution of proprietary branded pharmaceutical products. It generates a majority of its revenue from the Generic business segment.